Abstract
A head‐to‐head trial conducted at four European academic medical centers has found that the antipsychotic amisulpride was more efficacious than aripiprazole or olanzapine in reducing psychotic symptoms in patients with schizophrenia. Amisulpride is not marketed in the United States for the treatment of schizophrenia. Study results were published in the November 2020 issue of Lancet Psychiatry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
